Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 2Phase NA 1Phase 1/2 1Phase 1 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasm Metastasis 33Leukemia, Myeloid, Acute 24Melanoma 14Colorectal Neoplasms 14Breast Neoplasms 14Multiple Myeloma 13Myelodysplastic Syndromes 12Leukemia, Lymphocytic, Chronic, B-Cell 12Pancreatic Neoplasms 10Lymphoma, Follicular 10Prostatic Neoplasms 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, Large B-Cell, Diffuse 8Triple Negative Breast Neoplasms 7Lymphoma, Non-Hodgkin 7Lymphoma, Mantle-Cell 7Lung Neoplasms 7Burkitt Lymphoma 7Ovarian Neoplasms 6Lymphoma, B-Cell, Marginal Zone 6Stomach Neoplasms 5Sarcoma 5Lymphoma, T-Cell, Cutaneous 5Lymphoma, T-Cell 5Lymphoma, B-Cell 5Lymphoma 5Leukemia, Biphenotypic, Acute 5Carcinoma, Renal Cell 5Carcinoma, Non-Small-Cell Lung 5Unspecified Adult Solid Tumor, Protocol Specific 4

Interventions

pembrolizumab 26Gemcitabine 20Cisplatin 12Nivolumab 11Carboplatin 8Paclitaxel 7Docetaxel 7atezolizumab 6durvalumab 5Radiotherapy 5fludarabine 4enfortumab vedotin 4Ipilimumab 4Cyclophosphamide 4Vorinostat 3Magnetic Resonance Spectroscopy 3Fluorouracil 3Filgrastim 3Doxorubicin 3zimberelimab 2vocimagene amiretrorepvec 2tremelimumab 2romidepsin 2poly ICLC 2infigratinib 2erdafitinib 2cc-486 2belinostat 2avelumab 2amminedichloro(2-methylpyridine)platinum(II) 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Urinary Bladder Neoplasms × Biopsy × Clear all
NCT02496208 2026-05-13

Cabozantinib S-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors

National Cancer Institute (NCI)

Phase 1 Active not recruiting
152 enrolled
Genitourinary

Urinary Bladder Neoplasms, Carcinoma, Renal Cell, Penile Neoplasms, Ureteral Neoplasms, Urethral Neoplasms, Urogenital Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡